Interplay Bio

Executive Summary

Interplay Bio is a private biotechnology company headquartered in San Diego, California, founded in 2021. The company is dedicated to advancing drug discovery against historically "undruggable" protein targets by leveraging its proprietary LigandPro platform, which specializes in Targeted Protein Degradation (TPD) technology. Through the identification of novel small molecule ligands and molecular glues, Interplay Bio aims to expand the druggable proteome and enable precision therapeutics for diseases with high unmet medical need. As an early-stage company, Interplay Bio is operating in the rapidly evolving field of TPD, which has garnered significant interest from both academia and industry due to its potential to address targets that conventional small molecules cannot modulate. The company's focus on molecular glues—a subset of TPD that induces proximity between an E3 ligase and a target protein—positions it at the forefront of next-generation degradation approaches. Given the company's relatively recent inception and lack of publicly disclosed pipeline details, Interplay Bio is likely in the preclinical stage, focused on platform validation and lead optimization. The success of the LigandPro platform will depend on its ability to consistently generate high-quality degradation agents across multiple targets. In the near term, key milestones may include advancing candidate programs toward IND-enabling studies, securing additional financing to support R&D, and potentially establishing strategic partnerships with larger pharmaceutical companies. While the TPD space is competitive, Interplay Bio's unique platform and nimble structure could enable it to carve out a niche in undruggable targets, provided it can demonstrate robust preclinical efficacy and safety. The company's progress over the next 12–24 months will be critical to its trajectory.

Upcoming Catalysts (preview)

• Q3 2026Series A Financing Round70% success
• Q4 2026Lead Program Nomination for Key Target60% success
• H1 2027In Vivo Proof-of-Concept Data for Molecular Glue Platform50% success